Sickle cell disease: A multigenic perspective of a single-gene disorder

Medical Principles and Practice

Volumn 14, Issue SUPPL. 1, 2005, Pages 15-19

  Kutlar, Abdulla ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Genetic polymorphisms; Sickle cell disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; GLUCURONOSYLTRANSFERASE 1A1; URIDINE DIPHOSPHATE;

AVASCULAR NECROSIS; BILIRUBIN BLOOD LEVEL; CONFERENCE PAPER; DISEASE PREDISPOSITION; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PATHOGENESIS; PHENOTYPE; RISK FACTOR; SICKLE CELL ANEMIA; STROKE; VEIN THROMBOSIS;

ANEMIA, SICKLE CELL; BILIRUBIN; CEREBROVASCULAR ACCIDENT; FACTOR V; GENE EXPRESSION PROFILING; GENETIC DISEASES, INBORN; GENETIC MARKERS; GLUCURONOSYLTRANSFERASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; POLYMORPHISM, GENETIC;

EID: 23844549214     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086180     Document Type: Conference Paper

References (20)

1. Steinberg MH, Rodgers GP: Pathophysiology of sickle cell disease: Role of cellular and genetic modifiers. Semin Hematol 2001;38:299-306.
2. Hebbel RP, Vercellotti GM: The endothelial biology of sickle cell disease. J Lab Clin Med 1997;129:288-293.
3. Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, Bellevue R, Koshy M, Moohr JW, Smith J: Sickle cell disease as a cause of osteonecrosis of the Femoral Head. N Engl J Med 1991;325:1476-1481.
4. Kutlar A, Kutlar F, Turker I, Tural C: The methylene tetrahydrofolate reductase (C677T) mutation as a potential risk factor for avascular necrosis in sickle cell disease. Hemoglobin 2001;25:213-217.
5. Adekile AD, Kutlar F, Haider MZ, Kutlar A: Frequency of the 677C → T mutation of the methylenetetrahydrofolate reductase gene among Kuwaiti sickle cell disease patients. Am J Hematol 2001;66:263-266.
6. Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M: Incidence of activated protein C resistance caused by the ARG 5065 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995;86:219-224.
7. Le W, Yu JD, Tao R, You B, Cai X, Cao WJ, Huang W, He RM, Zhu DL, Chen Z, Gong LS: Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population. Clin Genet 2000;57:296-303.
8. Ustun C, Adams GT, Kutlar F, Elam D, Clair B, Daitch L: Factor V R485K polymorphism is a risk factor for catheter-induced thrombosis in sickle cell disease. 30th Anniversary of the National Sickle Cell Disease Program and the SCDAA, Washington, September 17-21, 2002.
9. Sampietro M, Lipica L, Perrero L, Comino A, Martinez di Montemuros F, Cappellini MD, Fiorelli G: The Expression of uridine diphosphate glucuronosyltransferase gene is a major determinant of bilirubin level in heterozygous β-thalassaemia and in glucose-6-phosphate dehydrogenase deficiency. Br J Haematol 1997;99:437-439.
10. McKie K, Kutlar F, Sromek E, Litaker M, Woods KF, Kutlar A: Uridine diphosphate glucuronosyl transferase-1 (UGTIAI) promoter polymorphism and bilirubin levels in patients with sickle cell disease. Blood 1999;94(suppl 1):861.
11. Passon RG, Howard TA, Zimmerman SA, Schultz WH, Ware RE: Influence of bilirubin uridine diphosphate-glucuronosyltransferase IA promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol 2001;23:448-451.
12. Henney MW, Howard TA, Zimmerman SA, Ware RE: UGT1A promoter polymorphism influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med 2003;141:279-282.
13. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM: Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-294.
14. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D: Prevention of a first stroke by transfusion in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
15. Driscoll MC, Hurlet A, Styles L, McKie V, Files B, Olivieri N, Pegelow C, Berman B, Drachtman R, Patel K, Brambilla D: Stroke risk in siblings with sickle cell anemia. Blood 2003;101:2401-2404.
16. Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L: Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 2003;101:2865-2869.
17. Taylor VI JG, Tang DG, Savage SA, Leitman SF, Heller SI, Serjeant GR, Rodgers GP, Chanock SJ: Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 2002;1000:4303-4309.
18. Nagel RL, Fabry ME, Kaul DK, Rybicki AC: Up-regulation of gene expression in the chronically damaged kidney in sickle transgenic mice. Blood 2002;100(suppl):2607.
19. Adewoye A, Safaya S, Frampton G, Lenburg M, Klings EX, Odhiambo A: Pulmonary artery endothelial cells exposed to acute chest syndrome plasma express a novel repertoire of genes. Blood 2002;100(suppl):1756.
20. Kutlar A, Kutlar F, Clair B, Nechtman J, Joshi RM, Daitch L: Gene expression profiling of peripheral blood cells from sickle cell patients with differing crisis rates. Blood 2002;100(suppl):3549.